Role of MicroRNAs in Regulation of Doxorubicin and Paclitaxel Responses in Lung Tumor Cells

Overview

Journal Cell Div

Publisher Biomed Central

Date 2023 Jul 21

PMID 37480054

Authors

Amirhosein Maharati

Meysam Moghbeli

Affiliations

Soon will be listed here.

Abstract

Lung cancer as the leading cause of cancer related mortality is always one of the main global health challenges. Despite the recent progresses in therapeutic methods, the mortality rate is still significantly high among lung cancer patients. A wide range of therapeutic methods including chemotherapy, radiotherapy, and surgery are used to treat lung cancer. Doxorubicin (DOX) and Paclitaxel (TXL) are widely used as the first-line chemotherapeutic drugs in lung cancer. However, there is a significant high percentage of DOX/TXL resistance in lung cancer patients, which leads to tumor recurrence and metastasis. Considering, the side effects of these drugs in normal tissues, it is required to clarify the molecular mechanisms of DOX/TXL resistance to introduce the efficient prognostic and therapeutic markers in lung cancer. MicroRNAs (miRNAs) have key roles in regulation of different pathophysiological processes including cell division, apoptosis, migration, and drug resistance. MiRNA deregulations are widely associated with chemo resistance in various cancers. Therefore, considering the importance of miRNAs in chemotherapy response, in the present review, we discussed the role of miRNAs in regulation of DOX/TXL response in lung cancer patients. It has been reported that miRNAs mainly induced DOX/TXL sensitivity in lung tumor cells by the regulation of signaling pathways, autophagy, transcription factors, and apoptosis. This review can be an effective step in introducing miRNAs as the non-invasive prognostic markers to predict DOX/TXL response in lung cancer patients.

Citing Articles

MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.

Lu X, Jin H Front Pharmacol. 2024; 15:1486783.

PMID: 39679367 PMC: 11638538. DOI: 10.3389/fphar.2024.1486783.

MicroRNA-98 as a novel diagnostic marker and therapeutic target in cancer patients.

Akhlaghipour I, Moghbeli M Discov Oncol. 2024; 15(1):385.

PMID: 39210158 PMC: 11362465. DOI: 10.1007/s12672-024-01270-z.

References

Katoh M . Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol. 2014; 2:61. PMC: 4207049. DOI: 10.3389/fcell.2014.00061. View

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

ostvold A, Norum J, Mathiesen S, Wanvik B, Sefland I, Grundt K . Molecular cloning of a mammalian nuclear phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo. Eur J Biochem. 2001; 268(8):2430-40. DOI: 10.1046/j.1432-1327.2001.02120.x. View

Moynahan M, Jasin M . Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010; 11(3):196-207. PMC: 3261768. DOI: 10.1038/nrm2851. View

Ireton R, Davis M, van Hengel J, Mariner D, Barnes K, Thoreson M . A novel role for p120 catenin in E-cadherin function. J Cell Biol. 2002; 159(3):465-76. PMC: 2173073. DOI: 10.1083/jcb.200205115. View

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

Schmittel A . Second-line therapy for small-cell lung cancer. Expert Rev Anticancer Ther. 2011; 11(4):631-7. DOI: 10.1586/era.11.7. View

Zhao Z, Manser E . PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation. Biochem J. 2004; 386(Pt 2):201-14. PMC: 1134783. DOI: 10.1042/BJ20041638. View

Vossler M, Yao H, York R, Pan M, Rim C, Stork P . cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell. 1997; 89(1):73-82. DOI: 10.1016/s0092-8674(00)80184-1. View

10.

Fan Z, Cui H, Yu H, Ji Q, Kang L, Han B . MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis. 2016; 5:e197. PMC: 5154343. DOI: 10.1038/oncsis.2016.1. View

11.

Wang L, Zhang M, Liu D . Knock-down of ABCE1 gene induces G1/S arrest in human oral cancer cells. Int J Clin Exp Pathol. 2014; 7(9):5495-504. PMC: 4203162. View

12.

Wu H, Liu X, Gong P, Song W, Zhou M, Li Y . Elevated TFAP4 regulates lncRNA TRERNA1 to promote cell migration and invasion in gastric cancer. Oncol Rep. 2018; 40(2):923-931. DOI: 10.3892/or.2018.6466. View

13.

Soria J, Lee H, Lee J, Wang L, Issa J, Kemp B . Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002; 8(5):1178-84. View

14.

Machida Y, Machida Y, Chen Y, Gurtan A, Kupfer G, DAndrea A . UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006; 23(4):589-96. DOI: 10.1016/j.molcel.2006.06.024. View

15.

Lu Y, Wang J, Liu L, Yu L, Zhao N, Zhou X . Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction. Tumour Biol. 2017; 39(4):1010428317698353. DOI: 10.1177/1010428317698353. View

16.

Zheng X, Chou P, Mirkin B, Rebbaa A . Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res. 2004; 64(5):1773-80. DOI: 10.1158/0008-5472.can-03-0820. View

17.

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H . Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch. 2005; 447(3):626-33. DOI: 10.1007/s00428-005-1228-0. View

18.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

19.

Sundaresan M, Yu Z, Ferrans V, Sulciner D, Gutkind J, Irani K . Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J. 1996; 318 ( Pt 2):379-82. PMC: 1217632. DOI: 10.1042/bj3180379. View

20.

Mishra A, Kumar R, Tyagi A, Kohaar I, Hedau S, Bharti A . Curcumin modulates cellular AP-1, NF-kB, and HPV16 E6 proteins in oral cancer. Ecancermedicalscience. 2015; 9:525. PMC: 4407748. DOI: 10.3332/ecancer.2015.525. View